• EVI

International partnership to advance the development of a new vaccine against Shigella and ETEC

Horizon2020 award to consortium will support the testing of an innovative live attenuated vaccine in phase I clinical trials in Europe and Bangladesh.

Under coordination by EVI, the SHIGETECVAX consortium, made up of partners including EVI, Eveliqure, icddr,b, University of Gothenburg, and PATH, will be advancing a radically new approach for a vaccine against Shigella and ETEC, developed by Eveliqure Biotechnologies.


To read the full EVI news release, please click this link:

http://www.euvaccine.eu/sites/default/files/uploads/Files/SHIGETECVAX_news%20relsease-EVI_FINAL_190910.pdf


To read the full EVQ news release, please click this link:

https://dd0878df-7f1d-4cd4-99b5-1a0d62bc3ecf.filesusr.com/ugd/e91f01_e2439e5923ab4779bb015763e62210d3.pdf


Join European Vaccine Initiative mailing list for updates on projects, training and funding opportunities

  • LinkedIn - White Circle
  • Twitter - White Circle

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 815568

© 2020 European Vaccine Initiative. Designed by European Vaccine Initiative